Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to -$2.9 million.

  • Heron Therapeutics' Change in Inventory fell 19526.9% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year increase of 51057.57%. This contributed to the annual value of $11.0 million for FY2024, which is 18866.24% up from last year.
  • Latest data reveals that Heron Therapeutics reported Change in Inventory of -$2.9 million as of Q3 2025, which was down 19526.9% from $16.0 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Change in Inventory ranged from a high of $16.0 million in Q2 2025 and a low of -$9.1 million during Q3 2022
  • Moreover, its 5-year median value for Change in Inventory was $391000.0 (2024), whereas its average is $1.5 million.
  • Its Change in Inventory has fluctuated over the past 5 years, first plummeted by 59946.07% in 2022, then surged by 690000.0% in 2024.
  • Heron Therapeutics' Change in Inventory (Quarter) stood at $6.9 million in 2021, then tumbled by 66.08% to $2.3 million in 2022, then crashed by 95.59% to $103000.0 in 2023, then surged by 6900.0% to $7.2 million in 2024, then crashed by 140.78% to -$2.9 million in 2025.
  • Its Change in Inventory stands at -$2.9 million for Q3 2025, versus $16.0 million for Q2 2025 and $3.8 million for Q1 2025.